Combination Chemotherapy for Advanced Bladder Cancer

Authors

  • R. R. HALL,

    Corresponding author
    1. Departments of Urology and Radiotherapy, University Hospitals, Newcastle upon Tyne
    Search for more papers by this author
    • 2

      R. R. Hall, MS, FRCS, Consultant Urologist, Freeman Hospital.

  • R. G. B. EVANS,

    1. Departments of Urology and Radiotherapy, University Hospitals, Newcastle upon Tyne
    Search for more papers by this author
    • 3

      R. G. B. Evans, MB, FRCR, DMRT, Consultant Radiotherapist, Royal Victoria Infirmary and Newcastle General Hospital.

  • C. J. PRITCHETT,

    1. Departments of Urology and Radiotherapy, University Hospitals, Newcastle upon Tyne
    Search for more papers by this author
    • 4

      C. J. Pritchett, MB, FRCS, Rotating Registrar in Surgery.

  • D. A. PRICE

    1. Departments of Urology and Radiotherapy, University Hospitals, Newcastle upon Tyne
    Search for more papers by this author
    • 5

      D. A. Price, MB, FRCS, Urological Registrar, Freeman Hospital.


Department of Urology, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne NE7 7DN.

Abstract

Summary— Adriamycin, bleomycin, 5-fluorouracil and methotrexate have been used in combination in a Phase II study and as adjuvant chemotherapy for patients with locally advanced bladder cancer. Although early results with metastatic disease showed considerable antitumour activity, longer follow-up has shown this drug combination to be ineffective.

Ancillary